July 6 | 2020
2cureX AB avser att genomföra en riktad nyemission av units
Read more
July 3 | 2020
2cureX AB expands its Board of Directors with Michael Lutz and Nils Brünner
Read more
July 3 | 2020
2cureX AB expands its Board of Directors with Michael Lutz and Nils Brünner
Read more
July 2 | 2020
Kommuniké från extra bolagsstämman i 2cureX AB (publ)
Read more
July 2 | 2020
Bulletin from the Extraordinary General Meeting in 2cureX AB (publ)
Read more
June 25 | 2020
2cureX receives third payment from the EU’ Horizon 2020 SME- Instrument Program
Read more
June 25 | 2020
2cureX receives third payment from the EU’ Horizon 2020 SME- Instrument Program
Read more
June 16 | 2020
2cureX AB establishes collaboration with Scandion Oncology A/S and Erasmus Medical Centre, Rotterdam, in drug-resistant breast cancer patients
Read more
June 16 | 2020
2cureX AB establishes collaboration with Scandion Oncology A/S and Erasmus Medical Centre, Rotterdam, in drug-resistant breast cancer patients
Read more
June 9 | 2020
Byte av Certified Adviser till Redeye AB
Read more
June 9 | 2020
Change of Certified Adviser to Redeye AB
Read more
May 29 | 2020
2cureX moves forward with the commercialization of IndiTreat by signing a new distributor agreement in Portugal
Read more
May 29 | 2020
2cureX moves forward with the commercialization of IndiTreat by signing a new distributor agreement in Portugal
Read more
May 28 | 2020
Communique from the Annual General Meeting in 2cureX AB (publ)
Read more
May 28 | 2020
Kommuniké från årsstämma i 2cureX AB (publ)
Read more
May 28 | 2020
2cureX offentliggör delårsrapport för det första kvartalet 2020
Read more
May 28 | 2020
2cureX publishes interim report for the first quarter of 2020
Read more
May 7 | 2020
2cureX offentliggör årsredovisning för räkenskapsåret 2019
Read more